Oppenheimer Asset Management Inc. boosted its position in shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) by 9.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,813 shares of the specialty pharmaceutical company’s stock after buying an additional 1,251 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Supernus Pharmaceuticals were worth $746,000 at the end of the most recent quarter.
Other large investors have also recently bought and sold shares of the company. SevenBridge Financial Group LLC acquired a new position in shares of Supernus Pharmaceuticals during the 2nd quarter worth approximately $113,000. Cubist Systematic Strategies LLC acquired a new position in shares of Supernus Pharmaceuticals during the 2nd quarter worth approximately $203,000. NumerixS Investment Technologies Inc acquired a new position in shares of Supernus Pharmaceuticals during the 2nd quarter worth approximately $204,000. Everence Capital Management Inc. acquired a new position in shares of Supernus Pharmaceuticals during the 2nd quarter worth approximately $205,000. Finally, Cim LLC acquired a new position in shares of Supernus Pharmaceuticals during the 2nd quarter worth approximately $207,000. Institutional investors own 99.10% of the company’s stock.
SUPN opened at $41.65 on Wednesday. Supernus Pharmaceuticals Inc has a one year low of $33.30 and a one year high of $61.25. The company has a market capitalization of $2.43 billion, a P/E ratio of 33.06 and a beta of 0.92. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.54 and a current ratio of 2.74.
Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings data on Tuesday, November 6th. The specialty pharmaceutical company reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of $0.42 by $0.10. Supernus Pharmaceuticals had a return on equity of 30.57% and a net margin of 24.17%. The firm had revenue of $102.99 million for the quarter, compared to analysts’ expectations of $100.75 million. During the same period in the prior year, the firm posted $0.29 earnings per share. The firm’s quarterly revenue was up 28.1% on a year-over-year basis. As a group, analysts anticipate that Supernus Pharmaceuticals Inc will post 1.93 EPS for the current year.
SUPN has been the topic of several recent research reports. Cantor Fitzgerald restated a “buy” rating and set a $56.00 target price on shares of Supernus Pharmaceuticals in a report on Friday, September 14th. Zacks Investment Research cut Supernus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, August 1st. Mizuho started coverage on Supernus Pharmaceuticals in a report on Monday, September 17th. They issued a “buy” rating and a $61.00 price objective on the stock. Piper Jaffray Companies set a $44.00 price objective on Supernus Pharmaceuticals and gave the company a “hold” rating in a report on Tuesday, August 28th. Finally, BidaskClub cut Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, September 19th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and seven have issued a buy rating to the company. Supernus Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $54.67.
WARNING: “Oppenheimer Asset Management Inc. Boosts Holdings in Supernus Pharmaceuticals Inc (SUPN)” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/11/07/oppenheimer-asset-management-inc-boosts-holdings-in-supernus-pharmaceuticals-inc-supn.html.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.
See Also: Short Selling Stocks and Day Traders
Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals Inc (NASDAQ:SUPN).
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.